Table S2 Adverse events reported by ≥1 participant in Trial A (SD-OCT formulation)

Preferred Term, n	Trial A Part 1 (Single dose of ubrogepant)					Trial A Part 2 (Once-daily ubrogepant for 10 days)				
	100 mg (*n* = 6)	100 mg Fed (n=6)	200 mg (*n* = 6)	400 mg (*n* = 6)	Placebo (n=6)	40 mg (*n* = 6)	100 mg (*n* = 6)	200 mg (*n* = 6)	400 mg (*n* = 6)	Placebo (n=8)
Participants with ≥1 AE	**1**	**1**	**2**	**0**	**2**	**2**	**3**	**2**	**4**	**5**
Vessel puncture site hematoma	1	0	0	0	0	0	0	0	0	0
Vessel puncture site paresthesia	1	0	0	0	0	0	0	0	0	0
Influenza like illness	0	0	1	0	0	0	0	1	0	0
Musculoskeletal stiffness	0	1	0	0	0	0	0	0	0	0
Somnolence	0	0	1	0	1	0	0	0	0	0
Nasopharyngitis	0	0	0	0	1	2	0	1	0	0
Headache	0	0	0	0	1	0	0	0	1	2
Puncture site pain	0	0	0	0	0	1	0	0	0	0
Nausea	0	0	0	0	0	0	1	0	1	2
Vomiting	0	0	0	0	0	0	1	0	0	1
Fatigue	0	0	0	0	0	0	1	0	0	0
Diarrhea	0	0	0	0	0	0	0	1	0	2

Gastroesophageal reflux disease	0	0	0	0	0	0	0	2	0	0
Abdominal discomfort	0	0	0	0	0	0	0	0	1	0
Abdominal pain	0	0	0	0	0	0	0	0	0	1
Abdominal pain upper	0	0	0	0	0	0	0	0	1	1
Application site irritation	0	0	0	0	0	0	0	0	1	0
Herpes simplex	0	0	0	0	0	0	0	0	1	0
Dry throat	0	0	0	0	0	1	0	0	0	0
Hand fracture	0	0	0	0	0	0	1	0	0	0
Nail injury	0	0	0	0	0	0	1	0	0	0
Wound	0	0	0	0	0	0	1	0	0	0
Oropharyngeal pain	0	0	0	0	0	0	0	1	0	0
Arthropod bite	0	0	0	0	0	0	0	0	1	0
Pain in extremity	0	0	0	0	0	0	0	0	0	1
Dizziness postural	0	0	0	0	0	0	0	0	0	2
Presyncope	0	0	0	0	0	0	0	0	0	1
Syncope	0	0	0	0	0	0	0	0	0	1

Note: 100 mg DFC and 40 mg HME formulation data not shown for Trial A.